Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT00493298
What this trial is testing

Tysabri Observational Program

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 6,620
Large-scale testing (Phase 3)UnknownNCT01333358
What this trial is testing

Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis
Central Texas Neurology Consultants 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT06663189
What this trial is testing

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
University Hospital, Strasbourg, France 200
Not applicableStudy completedNCT01541618
What this trial is testing

MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
MSDx, Inc. 15
Very early researchStudy completedNCT01040117
What this trial is testing

Sensori-motor Integration Training in Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Universita di Verona 80
Not applicableStudy completedNCT02305264
What this trial is testing

Imaging of Intracerebral Inflammation in MS

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Assistance Publique - Hôpitaux de Paris 61
Not applicableNot Yet RecruitingNCT06887426
What this trial is testing

Cladribine Tablets as an Exit Therapy Strategy

Who this might be right for
Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
University Hospital, Strasbourg, France 450
Large-scale testing (Phase 3)Study completedNCT00662649
What this trial is testing

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Novartis 920
Not applicableStudy completedNCT04565431
What this trial is testing

Examining Effects of Tysabri on Cognitive Fatigue Using fMRI

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Kessler Foundation 7
Not applicableStudy completedNCT05171972
What this trial is testing

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Southern California 40
Not applicableStudy completedNCT01031459
What this trial is testing

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Who this might be right for
Multiple Sclerosis
Bayer 176
Not applicableStudy completedNCT01915433
What this trial is testing

Wahls Paleo Diet and Progressive Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Terry L. Wahls 15
Not applicableActive Not RecruitingNCT05811416
What this trial is testing

Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Bristol-Myers Squibb 200
Post-approval studies (Phase 4)Ended earlyNCT03345940
What this trial is testing

Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta 55
Testing effectiveness (Phase 2)Study completedNCT01116427
What this trial is testing

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
National Institute of Allergy and Infectious Diseases (NIAID) 65
Large-scale testing (Phase 3)Study completedNCT00213135
What this trial is testing

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
EMD Serono 1,326
Testing effectiveness (Phase 2)Study completedNCT01457924
What this trial is testing

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
GlaxoSmithKline 232
Not applicableStudy completedNCT04833673
What this trial is testing

The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingPain, ChronicFatigue Syndrome, Chronic+1 more
Hacettepe University 80
Large-scale testing (Phase 3)Study completedNCT00548405
What this trial is testing

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genzyme, a Sanofi Company 840
Post-approval studies (Phase 4)Study completedNCT02142205
What this trial is testing

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 100
Next Page